Cannara Biotech Inc. is making waves on the TSX with a notable one-day gain, reflecting investor confidence in its recent performance.
Cannara Biotech Inc. (LOVE.TO) saw its stock price rise by 1.25% in the last trading session, closing at CA$1.62. This uptick comes amid strong revenue performance and strategic moves that are enhancing its market position.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Cannara Biotech Inc.
LOVE.TO
LOVE.TO
Cannara Biotech Inc.
WealthAwesomeMarket cap
$189.66M
P/E
17.5x
52W high
$2.05
52W low
$1.55
1W change
+5.59%
Beta
0.35
Analyst Price Targets
Based on analyst covering LOVE
Wall Street analysts forecast LOVE stock price to rise 78.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.38
+78.6% Upside
Current Price
C$1.89
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LOVE's historical volatility
30-Day Vol
40.2%
Annualized
90-Day Vol
35.2%
Annualized
Trend (90d)
+11.3%
Annualized drift
90d Mean
C$1.97
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$1.92 | C$1.67 โ C$2.20 |
| 60 trading days | C$1.94 | C$1.60 โ C$2.36 |
| 90 trading days | C$1.97 | C$1.55 โ C$2.50 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors are responding positively to Cannara Biotech's recent achievements and strategic initiatives, which may signal a strengthening financial outlook.
Cannara Biotech's Market Cap Reaches CA$163.98 Million
With a market cap of CA$163.98 million and a P/E ratio of 14.55, Cannara Biotech is positioned competitively within the cannabis sector, though investors should keep an eye on its profit margins.
Bull case
The company recently reported record net revenues of $107.3 million for fiscal 2025, showing strong growth and a shift towards profitability. This trend is likely to attract more investment interest.
Bear case
Despite the positive movement, potential investors should stay cautious. The cannabis market can be volatile, and Cannara's future performance will depend on continued growth and market conditions.
Recent Performance Highlights
Cannara Biotech's stock has seen a notable increase of 1.25% in the last trading session, closing at CA$1.62. This performance is supported by the company's recent reporting of record revenues and a shift towards profitability, marking a significant milestone in its financial journey.
Strategic Developments
The company has made strides in enhancing its market presence, including achieving DTC eligibility to facilitate U.S. investor access and completing a debt-to-equity conversion. These moves are expected to strengthen Cannara's balance sheet and attract further investment.
Looking Ahead
As Cannara Biotech prepares to release its Q3 2025 financial results, investors will be eager to see if the positive momentum continues. The upcoming results could provide further insights into the company's growth trajectory and market positioning.
Advertisement
